ALVR108: An allogeneic, off-the-shelf virus-specific T cell (VST) therapy targeting Human Herpesvirus-8


Serious Diseases Associate with Human Herpesvirus-8

HHV-8 is a herpesvirus that establishes life-long latency after primary infection. Though primary HHV-8 infection is usually asymptomatic, reactivation in immunocompromised individuals, such as those infected with human immunodeficiency virus, or HIV, or transplant recipients.

Reactivated Infections

A reactivated HHV-8 infection can result in a range of serious diseases, including Kaposi Sarcoma (KS), primary effusion lymphoma (PEL), and multi-centric Castleman’s disease (MCD). These diseases each lack effective standard of care treatments that can have a meaningful benefit for patients.

Development Plan

Preclinical data demonstrated that ALVR108 has potent antiviral activity against HHPV-8. ALVR108 may be provided to patients who are at risk of developing KS, PEL, or MCD.

The seroprevalence of human herpesvirus-8 is estimated to be between 1-5% in the United States, 10-20% in certain Mediterranean countries, and 30-80% in parts of sub-Saharan Africa.

Our Pipeline

Our allogeneic, off-the-shelf VST therapy candidates target 12 different devastating viruses to treat and prevent life-threatening viral diseases.

Expanded Access

Read our expanded access policy.

AlloVir is the Global Leader in Developing VST Immunotherapies

We develop highly innovative allogeneic, off-the-shelf VST therapy candidates designed to treat or prevent devastating viral infections and diseases.

Our Pipeline

Our allogeneic, off-the-shelf, VST therapy candidates target 12 different devastating viruses to treat or prevent life-threatening viral diseases.

Our Platform

Our proprietary platform develops allogeneic, off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies.

Our People

Our founders have a singular vision: to serve patients at risk of the devastating consequences of severe viral infections and diseases.